MX345729B - Proteina activadora del ensamblaje (aap) y su uso para la fabricacion de particulas de parvovirus que consisten esencialmente de vp3. - Google Patents
Proteina activadora del ensamblaje (aap) y su uso para la fabricacion de particulas de parvovirus que consisten esencialmente de vp3.Info
- Publication number
- MX345729B MX345729B MX2014014365A MX2014014365A MX345729B MX 345729 B MX345729 B MX 345729B MX 2014014365 A MX2014014365 A MX 2014014365A MX 2014014365 A MX2014014365 A MX 2014014365A MX 345729 B MX345729 B MX 345729B
- Authority
- MX
- Mexico
- Prior art keywords
- parvoviral
- aap
- polypeptides
- fragment
- nucleic acids
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title abstract 2
- 241000125945 Protoparvovirus Species 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 101710106719 Structural protein VP3 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15743609P | 2009-03-04 | 2009-03-04 | |
| US30620510P | 2010-02-19 | 2010-02-19 | |
| PCT/EP2010/001343 WO2010099960A2 (en) | 2009-03-04 | 2010-03-04 | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX345729B true MX345729B (es) | 2017-02-14 |
Family
ID=42313642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014365A MX345729B (es) | 2009-03-04 | 2010-03-04 | Proteina activadora del ensamblaje (aap) y su uso para la fabricacion de particulas de parvovirus que consisten esencialmente de vp3. |
| MX2011009193A MX2011009193A (es) | 2009-03-04 | 2010-03-04 | Proteina activadora del ensamblaje (aap) y su uso para la fabricacion de particulas de parvovirus que consisten esencialmente de vp3. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009193A MX2011009193A (es) | 2009-03-04 | 2010-03-04 | Proteina activadora del ensamblaje (aap) y su uso para la fabricacion de particulas de parvovirus que consisten esencialmente de vp3. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9464119B2 (enExample) |
| EP (1) | EP2403867B1 (enExample) |
| JP (2) | JP2012519008A (enExample) |
| CN (1) | CN102341406B (enExample) |
| BR (1) | BRPI1013364A2 (enExample) |
| CA (1) | CA2754335C (enExample) |
| DK (1) | DK2403867T3 (enExample) |
| ES (1) | ES2742180T3 (enExample) |
| MX (2) | MX345729B (enExample) |
| PL (1) | PL2403867T3 (enExample) |
| PT (1) | PT2403867T (enExample) |
| WO (1) | WO2010099960A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464119B2 (en) | 2009-03-04 | 2016-10-11 | Deutsches Krebsforschungszentrum | Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3 |
| WO2011100330A2 (en) * | 2010-02-12 | 2011-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for preventing or treating a human parvovirus infection |
| AR082925A1 (es) * | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| RU2487708C1 (ru) * | 2012-03-12 | 2013-07-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) | Способ лечения парвовирусной инфекции в19 у детей раннего возраста |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CN106414474B (zh) | 2014-03-17 | 2021-01-15 | 阿德夫拉姆生物技术股份有限公司 | 用于视锥细胞中增强的基因表达的组合物和方法 |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| CA2978068C (en) | 2015-03-02 | 2024-05-28 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| PT3872085T (pt) | 2015-07-30 | 2023-04-13 | Massachusetts Eye & Ear Infirmary | Sequências de aav ancestrais e utilizações destas |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| MX2018014152A (es) | 2016-05-18 | 2019-03-28 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la enfermedad de huntington. |
| US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| AU2018261790B2 (en) | 2017-05-05 | 2024-10-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| AU2018261003A1 (en) | 2017-05-05 | 2019-11-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's Disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| JP7221275B2 (ja) | 2017-08-03 | 2023-02-13 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖを送達するための組成物および方法 |
| CA3075656A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| US20200231986A1 (en) * | 2017-09-29 | 2020-07-23 | Massachusetts Eye And Ear Infirmary | Production of adeno-associated viruses in insect cells |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| US20190202866A1 (en) * | 2017-12-22 | 2019-07-04 | William Marsh Rice University | Viral nanoparticles and methods of use thereof |
| EP3527223A1 (en) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutated parvovirus structural protein |
| US11492377B2 (en) | 2018-02-16 | 2022-11-08 | 2A Pharma Ab | Parvovirus structural protein for the treatment of autoimmune diseases |
| US12421525B2 (en) | 2018-02-28 | 2025-09-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Conjugates comprising AAVs and CAS9 polypeptides |
| WO2019195549A1 (en) * | 2018-04-04 | 2019-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for engineered assembly activating proteins (eaaps) |
| WO2019195701A1 (en) | 2018-04-05 | 2019-10-10 | Massachusetts Eye And Ear Infirmary | Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation |
| EP3784697A4 (en) * | 2018-04-27 | 2022-07-06 | Spark Therapeutics, Inc. | Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| AU2019346655B2 (en) | 2018-09-28 | 2025-03-13 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CA3125411A1 (en) * | 2019-01-02 | 2020-07-09 | Intima Bioscience, Inc. | Modified adeno-associated viral vectors for use in genetic engineering |
| CA3128875A1 (en) | 2019-02-04 | 2020-08-13 | Freeline Therapeutics Limited | Polynucleotides |
| AU2020223149B2 (en) | 2019-02-15 | 2025-05-22 | Sangamo Therapeutics, Inc. | Compositions and methods for producing recombinant AAV |
| AU2020272557A1 (en) * | 2019-04-12 | 2021-12-09 | Ascend Gene And Cell Therapies Ltd | Plasmid system |
| AU2021215860A1 (en) * | 2020-02-07 | 2022-09-22 | Vecprobio, Inc. | Recombinant adeno-associated viral vectors in plants |
| KR20230078625A (ko) * | 2020-06-25 | 2023-06-02 | 페링 벤처스 에스에이 | 개선된 아데노 연관 바이러스 유전자 치료 벡터 |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| WO2024078584A1 (zh) * | 2022-10-13 | 2024-04-18 | 康霖生物科技（杭州）有限公司 | 腺相关病毒的衣壳蛋白编码基因改造方法 |
| CN117126270B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种2型人博卡病毒型别特异性抗体及其应用 |
| WO2025125222A1 (en) | 2023-12-11 | 2025-06-19 | Leukocare Ag | Compositions comprising viruses, viral vectors or virus-like particles |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4168062A (en) | 1977-12-05 | 1979-09-18 | Mccarthy Gerald F | Automated goalie |
| US6027722A (en) * | 1990-10-25 | 2000-02-22 | Nature Technology Corporation | Vectors for gene transfer |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| US20020052040A1 (en) * | 1999-06-30 | 2002-05-02 | Nicholas Hunt | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| DE19933719A1 (de) | 1999-07-19 | 2001-01-25 | Medigene Ag | Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung |
| JP2001169777A (ja) | 1999-07-30 | 2001-06-26 | Hiroshi Handa | アデノ随伴ウイルスのｖｐ３キャプシド蛋白質からウイルス様粒子を形成する方法 |
| US7638120B2 (en) * | 2000-03-14 | 2009-12-29 | Thomas Jefferson University | High transgene expression of a pseudotyped adeno-associated virus type |
| DE10024334B4 (de) | 2000-05-17 | 2006-06-01 | Medigene Ag | Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat |
| US6962815B2 (en) * | 2001-01-05 | 2005-11-08 | Children's Hopital Inc. | AAV2 vectors and methods |
| US7749492B2 (en) * | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| US20030103939A1 (en) * | 2001-07-13 | 2003-06-05 | Engelhardt John F. | Pseudotyped adeno-associated viruses and uses thereof |
| US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| NZ536274A (en) * | 2002-05-01 | 2008-04-30 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
| AU2003279240A1 (en) * | 2002-06-21 | 2004-01-06 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| US9464119B2 (en) | 2009-03-04 | 2016-10-11 | Deutsches Krebsforschungszentrum | Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3 |
-
2010
- 2010-03-04 US US13/203,442 patent/US9464119B2/en active Active
- 2010-03-04 EP EP10708716.5A patent/EP2403867B1/en active Active
- 2010-03-04 WO PCT/EP2010/001343 patent/WO2010099960A2/en not_active Ceased
- 2010-03-04 PT PT10708716T patent/PT2403867T/pt unknown
- 2010-03-04 PL PL10708716T patent/PL2403867T3/pl unknown
- 2010-03-04 CN CN201080010540.8A patent/CN102341406B/zh active Active
- 2010-03-04 MX MX2014014365A patent/MX345729B/es unknown
- 2010-03-04 ES ES10708716T patent/ES2742180T3/es active Active
- 2010-03-04 BR BRPI1013364A patent/BRPI1013364A2/pt not_active Application Discontinuation
- 2010-03-04 CA CA2754335A patent/CA2754335C/en active Active
- 2010-03-04 MX MX2011009193A patent/MX2011009193A/es active IP Right Grant
- 2010-03-04 DK DK10708716.5T patent/DK2403867T3/da active
- 2010-03-04 JP JP2011552364A patent/JP2012519008A/ja active Pending
-
2015
- 2015-10-09 JP JP2015200962A patent/JP6151328B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-12 US US15/263,072 patent/US10344057B2/en active Active
-
2019
- 2019-05-17 US US16/415,676 patent/US11267847B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200087352A1 (en) | 2020-03-19 |
| US9464119B2 (en) | 2016-10-11 |
| US11267847B2 (en) | 2022-03-08 |
| US20120135022A1 (en) | 2012-05-31 |
| EP2403867B1 (en) | 2019-05-22 |
| JP2016063810A (ja) | 2016-04-28 |
| WO2010099960A2 (en) | 2010-09-10 |
| ES2742180T3 (es) | 2020-02-13 |
| WO2010099960A3 (en) | 2011-01-13 |
| JP2012519008A (ja) | 2012-08-23 |
| CN102341406A (zh) | 2012-02-01 |
| BRPI1013364A2 (pt) | 2016-03-29 |
| CN102341406B (zh) | 2016-06-08 |
| PL2403867T3 (pl) | 2019-12-31 |
| CA2754335C (en) | 2019-12-24 |
| MX2011009193A (es) | 2011-12-16 |
| JP6151328B2 (ja) | 2017-06-21 |
| EP2403867A2 (en) | 2012-01-11 |
| CA2754335A1 (en) | 2010-09-10 |
| PT2403867T (pt) | 2019-08-29 |
| DK2403867T3 (da) | 2019-08-12 |
| US10344057B2 (en) | 2019-07-09 |
| US20170226160A1 (en) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX345729B (es) | Proteina activadora del ensamblaje (aap) y su uso para la fabricacion de particulas de parvovirus que consisten esencialmente de vp3. | |
| AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| WO2009076778A8 (en) | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin | |
| WO2012083445A8 (en) | Virus like particle production in plants | |
| ATE502108T1 (de) | Rsv f-protein und seine verwendung | |
| JP2014524241A5 (enExample) | ||
| MX363423B (es) | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. | |
| EA201492202A1 (ru) | Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк | |
| MX362028B (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
| WO2011034953A3 (en) | Lassa virus-like particles and methods of production thereof | |
| SG10201808730VA (en) | Cross-species-specific binding domain | |
| EP3130598A3 (en) | Expression sequences | |
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| JP2014503198A5 (enExample) | ||
| PT2170942E (pt) | Clone celular produtor de fsh | |
| BRPI0417159A (pt) | produção de partìcula semelhante a vìrus icosaédrico recombinante em pseudomÈnades | |
| WO2010086743A3 (en) | Codon-optimised hepatitis b virus core antigen | |
| BR112013017367A2 (pt) | polipeptídeo de alfacarpo, sequência de ácido nucléico, composição farmacêutica e método para a produção de pelo menos um polipeptídeo de alfacorpo | |
| MX2018007677A (es) | Operaciones de cosecha mejoradas para proteinas recombinadas. | |
| WO2012070795A3 (ko) | 고구마 유래의 ＩｂＯｒ-Ｉｎｓ 유전자 변이체 및 이의 용도 | |
| EP2600894A4 (en) | MODIFIED HEPATITIS C VIRUS PROTEINS | |
| JP2017524366A5 (enExample) | ||
| WO2008027560A3 (en) | Holin-enhanced vaccines and reagents, and methods of use thereof | |
| Xu et al. | Enhancement of recombinant human interleukin-22 production by fusing with human serum albumin and supplementing N-acetylcysteine in Pichia Pastoris | |
| RU2010125678A (ru) | Способ получения рекомбинантной вакцины |